Caicun Z. Zhou

No. 150 Jimo Road
Shanghai, 200120, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 130 publications

DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS <50% NSCLC.

DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS <50% NSCLC.

Journal: Future oncology (London, England)

Published: September 02, 2026

Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial.

Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: June 16, 2026

Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.

Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.

Journal: Lancet (London, England)

Published: April 22, 2026

Chinese expert consensus on radiotherapy combined with immunotherapy for unresectable lung cancer (2026 Edition).

Chinese expert consensus on radiotherapy combined with immunotherapy for unresectable lung cancer (2026 Edition).

Journal: Cancer letters

Published: March 15, 2026

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 05, 2025

Efficacy and safety of anti-LAG-3 IBI110 in combination with sintilimab and chemotherapy for advanced squamous non-small cell lung cancer: a randomized phase II study.

Efficacy and safety of anti-LAG-3 IBI110 in combination with sintilimab and chemotherapy for advanced squamous non-small cell lung cancer: a randomized phase II study.

Journal: Cancer immunology, immunotherapy : CII

Published: October 30, 2025

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.

Journal: Signal transduction and targeted therapy

Published: August 25, 2025

Bevacizumab plus chemotherapy versus chemotherapy in untreated advanced non-squamous non-small-cell lung cancer patients with brain metastases (BAP BRAIN): an open-label, randomized, multicenter, phase III study.

Bevacizumab plus chemotherapy versus chemotherapy in untreated advanced non-squamous non-small-cell lung cancer patients with brain metastases (BAP BRAIN): an open-label, randomized, multicenter, phase III study.

Journal: ESMO open

Published: August 18, 2025

Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer.

Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer.

Journal: Nature communications

Published: July 21, 2025

Bispecific T-cell Engager (CD3 × EGFR)-Based Triplet Therapy Unlocks CD40/CD40L Crosstalk to Revert Immunosuppression in Third-Generation EGFR-Tyrosine Kinase Inhibitor-Refractory NSCLC.

Bispecific T-cell Engager (CD3 × EGFR)-Based Triplet Therapy Unlocks CD40/CD40L Crosstalk to Revert Immunosuppression in Third-Generation EGFR-Tyrosine Kinase Inhibitor-Refractory NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: July 04, 2025

MARCO expression on myeloid-derived suppressor cells is essential for their differentiation and immunosuppression.

MARCO expression on myeloid-derived suppressor cells is essential for their differentiation and immunosuppression.

Journal: Cell death discovery

Published: March 13, 2025

Annual therapeutic advances in advanced non-small cell lung cancer in 2024

Annual therapeutic advances in advanced non-small cell lung cancer in 2024

Journal: Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases

Published: January 05, 2025

Showing 1-12 of 130

Last Updated: 09/26/2026